NCT00006244View on ClinicalTrials.gov

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
Interventions
DRUG

melphalan

Given IV

BIOLOGICAL

recombinant interferon alfa

Given SC

BIOLOGICAL

aldesleukin

Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00006244 - Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma | Biotech Hunter | Biotech Hunter